Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysisCommentary: Dosage needs systematic and critical review

Open access
Holt, Shaun, Herxheimer, Andrew, Suder, Aneta, Weatherall, Mark, Cheng, Soo, Shirtcliffe, Philippa, Beasley, Richard·2001·BMJ

Abstract

Objective: To examine the dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma. Design: Meta-analysis of placebo controlled, randomised clinical trials that presented data on at least one outcome measure of asthma and that used at least two different doses of fluticasone. Setting: Medline, Embase, and GlaxoWellcome's internal clinical study registers. Main outcome measures: FEV 1 , morning and evening peak expiratory flow, night awakenings, β agonist use, and major exacerbations. Results: Eight studies, with 2324 adolescents and adults with asthma, met the inclusion criteria. Data on doses of >500 µg/day were limited. The dose-response curve for the raw data began to reach a plateau at around 100-200 µg/day and peaked by 500 µg/day. A negative exponential model for the data, without meta-analysis, indicated that 80% of the benefit at 1000 µg/day was achieved at doses of 70-170 µg/day and 90% by 100-250 µg/day. A quadratic meta-regression showed that the maximum achievable efficacy was obtained by doses of around 500 µg/day. The odds ratio for patients remaining in a study at a dose of 200 µg/day, compared with higher doses, was 0.73 (95% confidence interval 0.49 to 1.08). Comparison of the standardised difference in FEV 1 for an inhaled dose of 200 µg/day against higher doses showed a difference in FEV 1 of 0.13 of a standard deviation (−0.02 to 0.29). Conclusions: In adolescent and adult patients with asthma, most of the therapeutic benefit of inhaled fluticasone is achieved with a total daily dose of 100-250 µg, and the maximum effect is achieved with a dose of around 500 µg/day. However, these findings were limited by the lack of data on individual patients and by the paucity of dose-response studies that included doses of >500 µg/day. What is already known on this topic: Inhaled corticosteroids are recommended for most patients with asthma, with the dose being increased as required to obtain control A therapeutic dose range of fluticasone propionate of 200-2000 µg/day is recommended in the British National Formulary for adults with asthma What this study adds: Published data are insufficient to determine with confidence the dose-response relation of inhaled fluticasone at doses of >500 µg/day The dose-response curve for inhaled fluticasone in moderate to severe asthma in adolescents and adults, for all major clinical outcome measures, including exacerbations, begins to plateau at 100-200 µg/day and peaks at around 500 µg/day This study partially explains why adding a long acting β agonist to inhaled corticosteroids is more efficacious than increasing the dose of inhaled steroid beyond this dose range

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.323.7307.253

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 226

Metadata

Authors
Holt, S., Herxheimer, A., Suder, A., Weatherall, M., Cheng, S., Shirtcliffe, P., & Beasley, R.
Venue
BMJ
Publisher
BMJ
Published
2001-08-04
Volume
323
Issue
7307
Pages
253
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2049638018
Cited by
226
References
3
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysisCommentary: Dosage needs systematic and critical review. https://app.cochat.ai/papers/10.1136/bmj.323.7307.253
The paper
Holt, S., Herxheimer, A., Suder, A., Weatherall, M., Cheng, S., Shirtcliffe, P., & Beasley, R. (2001). Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysisCommentary: Dosage needs systematic and critical review. BMJ. https://doi.org/10.1136/bmj.323.7307.253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.